Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage kidney disease (ESKD). The disorder is characterized by development and continued growth of multiple cysts requiring renal replacement therapy in 50% of patients by age 60 years. However, ADPKD is also a complex metabolic disorder defined by insulin resistance (IR) and mitochondrial dysfunction which may be causally related to cyst expansion, kidney function decline and contribute to reduced life expectancy. Renal hypoxia, stemming from a potential metabolic mismatch between increased renal energy expenditure and impaired substrate utilization, is proposed as a novel unifying early pathway in the development and expansion of renal cysts in ADPKD. By examining the interplay between renal O2 consumption and energy utilization in young adults with and without ADPKD, the investigators hope to identify novel therapeutic targets to impede development of cyst expansion in future trials. The investigators propose to address the specific aims in a cross-sectional study with 20 adults with ADPKD (50% female, ages 18-40 years). Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance). For this protocol, participants will complete a one day study visit at Children's Hospital Colorado. Patients will undergo a dual energy x-ray absorptiometry (DXA) to assess body composition, and a 11C-acetate positron emission tomography (PET/CT) scan to quantify renal O2 consumption. After the PET/CT, participants will undergo a hyperinsulinemic-euglycemic clamp while fasting to quantify insulin sensitivity. Glomerular Filtration Rate (GFR) and Effective Renal Plasma Flow (ERPF) will be measured by iohexol and PAH clearances during the hyperinsulinemic-euglycemic clamp.
Study Type
OBSERVATIONAL
Enrollment
22
Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Imaging used to visualize the kidneys and quantify renal metabolic activity
Children's Hospital Colorado
Aurora, Colorado, United States
Renal oxygen consumption
11-C Acetate PET/CT
Time frame: 30 minutes
Insulin Sensitivity
Hyperinsulinemic-Euglycemic Clamp
Time frame: 4.5 hours
Mitochondrial Function
Blood draw for mitochondrial DNA copy number
Time frame: 5 minutes
Mitochondrial Function
Blood draw for untargeted metabolite assessment of the tricyclic acid (TCA) cycle
Time frame: 5 minutes
Mitochondrial Function
Blood draw for targeted assessment and quantification of glucose oxidation using an established metabolite panel
Time frame: 5 minutes
Mitochondrial Function
Blood draw for untargeted metabolite assessment of Free Fatty Acid (FFA) oxidation
Time frame: 5 minutes
Glomerular Filtration Rate (GFR)
Iohexol Clearance Study
Time frame: 3 hours
Effective Renal Plasma Flow (ERPF)
PAH Clearance Study
Time frame: 2.5 hours
Renin-Angiotensin-Aldosterone-System Activity
Blood draw for Plasma Renin levels
Time frame: 5 minutes
Renin-Angiotensin-Aldosterone-System Activity
Blood draw for Angiotensin II levels
Time frame: 5 minutes
Renin-Angiotensin-Aldosterone-System Activity
Blood draw for Copeptin levels
Time frame: 5 minutes
Kidney Injury Biomarkers
Chitinase-3-like protein 1 (YKL-40) levels
Time frame: 5 minutes
Kidney Injury Biomarkers
Blood draw for Neutrophil gelatinase-associated lipocalin (NGAL) levels
Time frame: 5 minutes
Kidney Injury Biomarkers
Blood draw for Kidney Injury Molecule 1 (KIM-1) levels
Time frame: 5 minutes
Kidney Injury Biomarkers
Blood draw for Interleukin-18 (IL-18) levels
Time frame: 5 minutes
Kidney Injury Biomarkers
Blood draw for Tumor Necrosis Factor Receptor 1/2 (TNF-R 1/2) levels
Time frame: 5 minutes
Kidney Injury Biomarkers
Blood draw for monocyte chemoattractant protein-1 (MCP-1) levels
Time frame: 5 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.